 Up to 1000 patients 12 to 40 years of age inclusive will be enrolled to have 870 patients in the modified intent-to-treat mITT population and 579 patients in the per-protocol PP population. The primary inclusion criteria are the presence of 20 inflammatory lesions papules and pustules and 25 non-inflammatory lesions opened and closed comedones and 2 nodulocystic lesions i.e., nodules and cysts on the face and an Investigators Global Assessment IGA score of 3 or 4. 